Expression of leukotriene B4 receptor 1 defines functionally distinct DCs that control allergic skin inflammation

Tomoaki Koga1,2, Fumiyuki Sasaki1,2, Kazuko Saeki1, Soken Tsuchiya3, Toshiaki Okuno1, Mai Ohba1, Takako Ichiki1, Satoshi Iwamoto4, Hirotsugu Uzawa1, Keiko Kitajima5, Chikara Meno5, Eri Nakamura6, Norihiro Tada6, Yoshinori Fukui7, Junichi Kikuta8, Masaru Ishii8, Tomoaki Koga1,2, Fumiyuki Sasaki1,3, Kazuko Saeki1, Soken Tsuchiya4, Toshiaki Okuno1, Mai Ohba1, Takako Ichiki1, Satoshi Iwamoto5, Hirotsugu Uzawa1, Keiko Kitajima5, Chikara Meno5, Eri Nakamura6, Norihiro Tada6, Yoshinori Fukui7, Junichi Kikuta8, Masaru Ishii8, Yukihiko Sugimoto4, Mitsuyoshi Nakao2 and Takehiko Yokomizo3

Leukotriene B4 (LTB4) receptor 1 (BLT1) is a chemotactic G protein-coupled receptor expressed by leukocytes, such as granulocytes, macrophages, and activated T cells. Although there is growing evidence that BLT1 plays crucial roles in immune responses, its role in dendritic cells remains largely unknown. Here, we identified novel DC subsets defined by the expression of BLT1, namely, BLT1hi and BLT1lo DCs. We also found that BLT1hi and BLT1lo DCs differentially migrated toward LTB4 and CCL21, a lymph node-homing chemoattractant, respectively. By generating LTB4-producing enzyme LTA4H knockout mice and CD11c promoter-driven Cre recombinase-expressing BLT1 conditional knockout (BLT1 cKO) mice, we showed that the migration of BLT1hi DCs exacerbated allergic contact dermatitis. Comprehensive transcriptome analysis revealed that BLT1hi DCs preferentially induced Th1 differentiation by upregulating IL-12p35 expression, whereas BLT1lo DCs accelerated T cell proliferation by producing IL-2. Collectively, the data reveal an unexpected role for BLT1 as a novel DC subset marker and provide novel insights into the role of the LTB4-BLT1 axis in the spatiotemporal regulation of distinct DC subsets.

Keywords: LTB4; BLT1; dendritic cells; inflammation; lipid mediator

Cellular & Molecular Immunology (2021) 18:1437–1449; https://doi.org/10.1038/s41423-020-00559-7

INTRODUCTION

Dendritic cells (DCs) are specialized antigen-presenting cells that reside at host-environment boundaries, such as the skin, lungs, and intestine. DCs capture antigens in the periphery and migrate toward draining lymph nodes. Migrated DCs activate naïve T cells by presenting antigen-loaded MHC class II molecules and by producing cytokines that induce T cell differentiation (i.e., interleukin [IL]-12 for Th1 cells; IL-4 for Th2 cells; IL-6, IL-23, and transforming growth factor [TGF]-β for Th17 cells; and TGF-β for regulatory T cells [Tregs]). Thus, DCs are a crucial “control tower” for acquired immune responses. In addition, recent reports show that in addition to migrating to lymph nodes, DCs migrate toward peripheral inflammatory areas to form DC-T cell clusters; both pathways are important for efficient antigen presentation and T cell expansion.1–4 Thus, the migratory and cytokine-producing abilities of DCs are crucial for efficient control of acquired immune responses.

Acquired immunity is mediated by cytokines, chemokines, noncoding RNAs, and lipid mediators. Growing evidence suggests that among these factors, lipid mediators are involved in accelerating and regulating immunological responses. A classical lipid mediator, prostaglandin E2 (PGE2), and its receptor, EP4, promote immune inflammation associated with contact hypersensitivity and experimental autoimmune encephalomyelitis (EAE) by inducing the differentiation and expansion of Th1 and Th17 cells.5,6 Another lipid mediator, sphingosine 1 phosphate (S1P), is a lysophospholipid that attracts activated T cells in the lymph nodes to efferent lymphatic vessels, thereby amplifying acquired immune responses. Indeed, FTY720 (fingolimod), a functional antagonist of the S1P receptor S1P1, is used as a drug to treat autoimmune diseases such as multiple sclerosis because it inhibits the S1P-S1P1-dependent egress of lymphocytes from the lymph nodes and reduces the recirculation of autoaggressive T cells.7,12 An alternative proresolutive lipid mediator, resolin E1 (RvE1), inhibits DC migration to the skin and attenuates contact dermatitis.13 Furthermore, phospholipase A2 group IID resolves inflammatory lipid mediators, including RvD1 and 15-deoxy-Δ12,14-prostaglandin J2.14 Advances in lipid detection methods (e.g., LC-MS/MS) have led to the discovery of more than 100,000 species of lipids within the human body; however, the functions of lipids during acquired immune responses remain largely unknown.
Leukotriene B\(_4\) (LT\(_B_4\)) is a classic inflammatory lipid mediator produced by myeloid cells such as granulocytes, macrophages, and DCs.\(^{15-18}\) LT\(_B_4\) is generated from arachidonic acid by 5-lipoxygenase (5-LOX), 5-LOX-activating protein (FLAP), and LTA\(_4\) hydrolase (LTA\(_4\)H). Previously, we cloned BLT1 as a high-affinity receptor for LT\(_B_4\).\(^{13\text{a},13\text{b}}\) BLT1 is a G-protein-coupled receptor expressed by neutrophils, eosinophils, macrophages, DCs, and activated T cells and is conserved from zebrafish to mammals.\(^{20-30}\)

We generated BLT1-deficient mice and used them to show that BLT1 plays detrimental roles in Th1-, Th2-, and Th17-dependent diseases.\(^{26,31,32}\) Wang et al. further demonstrated that BLT1 is expressed by CD4\(^+\)/CD25\(^+\)/Foxp3\(^+\) Tregs and promotes resolution of acute lung injury.\(^{33}\) Moreover, Goodarzi et al. showed that BLT1 expression is greatly induced in CD8\(^+\) T cells during differentiation into effector cells and promotes T cell recruitment to inflamed tissues.\(^{29}\) Thus, BLT1 acts as a crucial player during acquired immune responses. However, since BLT1 is expressed by various leukocytes, its cell-specific role in acquired immunity remains largely unknown.

Here, we developed an anti-mouse BLT1 monoclonal antibody,\(^{34,35}\) LT\(_A_4\)H-deficient mice, and CD11c promoter-driven Cre recombines-expressing BLT1 conditional knockout (cKO) mice and used these tools to examine the role of BLT1 specifically expressed by DCs. The results revealed the immune response-amplifying function of BLT1 expressed by DCs and the presence of novel DC subsets defined by the expression levels of BLT1, namely, BLT1\(^{hi}\) and BLT1\(^{lo}\) DCs. Furthermore, we show that these DCs play critical immune roles by generating distinct cytokine profiles and exhibiting different migratory activities. Taken together, these findings provide new insights into the DC-specific role of the LT\(_B_4\)-BLT1 axis during the immune response and suggest new therapeutic targets for immune-mediated diseases, such as delayed-type allergic contact dermatitis.

**MATERIALS AND METHODS**

Reagents and antibodies

2,4-Dinitrofluorobenzene (DNFB), 2,4-dinitrobenzenesulfonate (DNBS), an ovalbumin (OVA) peptide (323–339), and lipopolysaccharide (LPS) were purchased from Sigma-Aldrich (St. Louis, MO, USA). LT\(_B_4\) and U75302 were purchased from Cayman Chemical (Ann Arbor, MI, USA). CpG DNA was purchased from InvivoGen (San Diego, CA, USA). Murine GM-CSF was purchased from PeproTech (London, UK). CellTracker Green S-Cloromethylfluorescein diacetate (CMFDA) and CellTracker Red CMTPX were purchased from Invitrogen (Carlsbad, CA, USA). A recombinant mouse CCL21 protein and recombinant IL-2 protein were purchased from R&D Systems (Minneapolis, MN, USA). The anti-mouse BLT1 monoclonal antibody 7A8 was generated in-house, and biotinylation was performed using the EZ-link sulfo-NHS-Biotin Kit (Pierce-Thermo Fisher Scientific, Rockford, IL, USA). An anti-mouse BLT1 rabbit polyclonal antibody was generated in-house by immobilizing a rabbit with the C-terminal peptide of mouse BLT1 (DSFMTSSTSPESX). The antibody was affinity-purified using a peptide antigen. A FITC-conjugated anti-CD11c antibody, a phycoerythrin (PE)-conjugated anti-MHC class II antibody, streptavidin (SA)-allophycocyanin (APC), 7-amino actinomycin D (7-AAD), a PE-conjugated anti-CD80 antibody, a PE-conjugated anti-CD86 antibody, a PE-conjugated anti-B220 antibody, a PE-conjugated anti-CD11b antibody, a FITC-conjugated anti-IFN-\(\gamma\) antibody, an anti-IL-12p40 antibody, a PerCP-Cyanine 5.5-conjugated anti-CD4 antibody, biotin-conjugated mouse IgG1, and rat IgG3 antibodies were purchased from ebioscience (San Diego, CA, USA). An anti-IL-12p35 antibody was purchased from Invitrogen. An anti-phospho-ERK1/2 antibody and Na\(^+\)-K\(^+\) ATPase-specific antibodies were purchased from Cell Signaling Technology (Danvers, MA, USA). An anti-ERK2 antibody and anti-\(\beta\)-actin antibody were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA).

Lipid extraction and LC-MS/MS

BMDCs (1 × 10\(^6\) cells) derived from LTA\(_4\)H WT, heterozygous, or KO mice were stimulated for 30 min with 2 \(\mu\)M A23187, and the culture supernatants were collected. The same amount of ice-cold methanol was added to each sample. Frozen ears from mice with allergic dermatitis were crushed using an SK mill (Tokken Inc., Chiba, Japan), and lipids were extracted by the addition of methanol, followed by centrifugation. LC-MS/MS analyses were performed as described below. Prepared samples were diluted in a dilution solution (waterformic acid [100:0.1, v/v]). An internal standard mixture was then added, and the samples were loaded onto C18 cartridges (Oasis HLB cartridge, Waters, Milford, MA). These cartridges were then washed with a washing solution (waterformic acid [100:0.1, v/v]; water:methanol:formic acid [100:0.1, v/v]); and petroleum etherformic acid [100:0.1, v/v]). Fatty acid-enriched samples were eluted into glass vials using 200 \(\mu\)l of methanol containing 0.1% formic acid. The samples were then analyzed by tandem LC-MS/MS. A Prominence HPLC system (Shimadzu, Kyoto, Japan) and TSQ Quantum Ultra triple-stage quadrupole mass spectrometer were connected in tandem. The mobile phases A and B comprised water and acetonitrile with 0.1% formic acid, respectively. Separation and enrichment were performed using a Capcell Pak C18 MGS3 separating column (Shiseido, Tokyo, Japan) and an Opti-Guard Mini C18 trapping column (Optimize Technologies, Oregon City, OR, USA). The conditions used to detect LT\(_B_4\) were as follows: retention time (min), 10.98; precursor ion (m/z), 335; product ion (m/z), 195; and collision energy (V), 16. Data were analyzed using XCalibur 2.1 (Thermo Fisher Scientific).

DNA microarray analysis

Total RNA was extracted from BLT1\(^{hi}\) and BLT1\(^{lo}\) DCs (treated with LPS or CpG DNA or left untreated for 4 h) using TRIzol reagents. cDNA was prepared and labeled using the Ambion WT Expression Kit (Affymetrix, San Diego, CA, USA) and GeneChip WT Terminal Labeling Kit (Affymetrix). The labeled samples were subjected to hybridization with the GeneChip Hybridization Wash, Stain Kit (Affymetrix) and GeneChip Mouse Gene 1.0 ST array (Affymetrix). Signals were scanned with a GeneChip Scanner 3000 7 G, and data were analyzed using Affymetrix Expression Console software (Affymetrix). The robust multiairray average algorithm was used for log2 transformation and normalization of the GeneChip data. Hierarchical clustering analysis was performed using R (www.r-project.org). Functional enrichment analysis of selected genes was performed based on GO pathway annotation terms, with \(P\) values < 0.05 considered statistically significant.

**Flow cytometric analysis, cell sorting, and DC culture**

Single cells were prepared as described below. Briefly, tissues were collected from mice, cut into small pieces with scissors, and incubated in a collagenase solution (1 mg/ml collagenase and 0.04 mg/ml DNase I in PBS) for 30 min at 37 °C. The reaction was stopped by the addition of a stopping solution (10% FBS and 10 mM EDTA in PBS). Red blood cells were lysed with red blood cell lysis buffer (150 mM NH\(_4\)Cl, 12.5 mM NaHCO\(_3\), and 0.1 mM EDTA). The cells were resuspended in FACS buffer (2% FBS in PBS), blocked with an anti-FcgRIII/I antibody (2.4G10), and stained with primary antibodies (anti-CD11c, anti-MHC class II, anti-mouse BLT1, anti-CD80, anti-CD86, anti-B220, or anti-CD11b). The anti-mouse BLT1 antibody was visualized with SA-APC. Dead cells were stained with 7-AAD, and 7-AAD-negative (live) cells were analyzed. In some experiments, labeled splenic DCs were sorted using a FACSaria. For BMDC differentiation, bone marrow cells were collected from the femurs and tibias of C57BL/6J mice with a syringe and 27 G needle. Cells (1 × 10\(^6\) cells/ml) were cultured for 6 days in DC medium (RPMI-1640 medium supplemented with 10% fetal bovine serum [FBS], 50 \(\mu\)M 2-mercaptoethanol, 10 ng/ml mouse GM-CSF, 100 U/ml penicillin, and 100 \(\mu\)g/ml streptomycin) for...
Fig. 1  BLT1-positive and BLT1-negative DC subsets. 

a Schematic representation of LTB4 production. Arachidonic acid released from membrane phospholipids is converted into LTA4 by the enzymes 5-LOX and FLAP. LTB4 is generated from LTA4 by the enzyme LTA4H. LTB4 acts as an endogenous ligand for the BLT1 receptor. LTA4 is also converted into CysLTs (LTC4, LTD4, and LTE4).

b Splenocytes were stained with antibodies specific for CD11c, MHC class II, and mouse BLT1. CD11c+/MHC class II+DCs were analyzed using an anti-mouse BLT1 monoclonal antibody (7A8).

c BMDCs were stained with antibodies specific for CD11c, MHC class II, and BLT1.

d Immuno-fluorescence staining of the mouse spleen was performed using anti-CD11c and anti-mouse BLT1 antibodies. Closed arrowheads indicate BLT1-positive DCs; open arrowheads indicate BLT1-negative DCs.

e CD11c+/BLT1+BLT1hi DCs and CD11c+/BLT1-BLT1lo DCs derived from BMDCs were sorted and stained with a Diff-Quik solution.

f CD11c+/BLT1+BLT1hi DCs and CD11c+/BLT1-BLT1lo DCs derived from BMDCs were sorted and stained with a Diff-Quik solution.

g LN DCs were stained with antibodies specific for B220 and CD11b. The percentage of cells in the violet square is shown.

h A schematic summary of the relationships among BLT1hi DCs, BLT1lo DCs, CD11b+cDCs, CD11b-cDCs, and B220+pDCs is shown.
Expression of leukotriene B4 receptor 1 defines... T Koga et al.

6 days in 24-well plates (Sumilon, Tokyo, Japan) at 37 °C in an atmosphere of 5% CO₂. The medium was changed every 2 days. On Day 4, floating cells were washed away. On Day 6, cells were stained and sorted using a FACSAria II flow cytometer (BD Biosciences).

Immunofluorescence staining

Spleens were collected from C57BL/6J mice and embedded in O.C.T. compound (Sakura Finetek, Tokyo, Japan). Sections (5 μm thickness) were prepared using a cryostat (Leica, Wetzler, Germany). Tissue sections were fixed for 10 min in cold acetone, washed, and blocked for 30 min with 5% bovine serum albumin. The sections were incubated with primary antibodies specific for murine BLT1 (rabbit polyclonal antibody) and CD11c (FITC-conjugated antibody), followed by incubation with a biotin-conjugated anti-rabbit IgG antibody and SA-Alexa Fluor 594 in sequence. The stained sections were visualized with an Axiovert (Carl Zeiss, Gottingen, Germany).

Mice and genotyping

C57BL/6J mice were purchased from Japan SLC (Shizuoka, Japan). Ltb4r1tm1a(EUCOMM)Hmgu embryonic stem (ES) cells (clone H11) were purchased from EUCOMM (ID: 45475) and used to generate chimeric mice via the aggregation method. Ltb4r1tm1a(EUCOMM)Hmgu mice were crossed with CAG-FLP-Fg Tg mice to remove the region containing the LacZ-neomycin cassette between the FRTs and then crossed with wild-type C57BL/6J mice to remove the FLPe gene to generate BLT1floxflo mice. BLT1floxflo mice were then crossed with Cd11c-Cre Tg mice. Microinjection of 50 μl of 0.5% DNFB (in acetone/olive oil [4:1]) to a shaved abdominal site on Day 0, followed by application of 20 μl of 0.3% DNFB to the right ear on day 5. Ear thickness was measured using a digital micrometer (Mitutoyo, Tokyo, Japan). At 48 h postchallenge, the ears were collected and subjected to histological and QPCR analyses. For adoptive transfer, BLT1hi and BLT1lo DCs derived from BMDCs were sorted and loaded with 1 mM DNBS for 6 h in vitro. The hapten-loaded DCs were washed twice with PBS, followed by staining with antibodies to examine T helper cells (Th1, Th2, and Th17) and CD8+ T cells. The stained cells were analyzed with a FACSAria II flow cytometer (BD Biosciences).

Real-time quantitative RT-PCR (QPCR)

Total RNA was extracted from various murine tissues, including the ear, splenic DCs, and BMDCs, using TRIzol reagent. Reverse transcription (RT) was performed using a high-capacity cDNA reverse transcription kit (Thermo Fisher Scientific). The primer sequences used in this study were as follows: mouse BLT1 Fw: 5′-ATGGCTGCAAACACTACCATCT-3′ and mouse BLT1 Rv: 5′-GACCGTGGTGTTTCTGCATC-3′; mouse IL-12p35 Fw: 5′-AGACATCACAGGCCACCA-3′ and mouse IL-12p35 Rv: 5′-CCAGGCAACTCTGGCTTGTG-3′; mouse IL-12p40 Fw: 5′-TGTGTTGATCAGTGGTG-3′ and mouse IL-12p40 Rv: 5′-ACAGGTGAGGTTCAAGGGTT-3′; and mouse IL-2 Fw: 5′-TCAGGAGAGTTAGGAAATTACAGG-3′ and mouse IL-2 Rv: 5′-GTCCACTCTCTTCTCTACGAC-3′; mouse GAPDH Fw: 5′-GAGAGCTGACTACGCC-3′ and mouse GAPDH Rv: 5′-GACGGCACTCTACGC-3′. Cytokine bead array data were analyzed using a FACSDiva software (BD Biosciences). The mouse model of contact dermatitis used in this study was described previously.6,37 Briefly, mice were sensitized by application of 50 μl of 0.5% DNFB (in acetone/olive oil [4:1]) to a shaved abdominal site on Day 0, followed by application of 20 μl of 0.3% DNFB to the right ear on day 5. Ear thickness was measured using a digital micrometer (Mitutoyo, Tokyo, Japan). At 48 h postchallenge, the ears were collected and subjected to histological and QPCR analyses. For adoptive transfer, BLT1hi and BLT1lo DCs derived from BMDCs were sorted and loaded with 1 mM DNBS for 6 h in vitro. The hapten-loaded DCs were washed twice with PBS, followed by staining with CD4, CD8, and CD11c antibodies. The stained cells were analyzed with a FACSAria II flow cytometer (BD Biosciences).

Delayed-type contact dermatitis and adoptive transfer

The mouse model of contact dermatitis used in this study was described previously.9,36 Briefly, mice were sensitized by application of 50 μl of 0.5% DNFB (in acetone/olive oil [4:1]) to a shaved abdominal site on Day 0, followed by application of 20 μl of 0.3% DNFB to the right ear on day 5. Ear thickness was measured using a digital micrometer (Mitutoyo, Tokyo, Japan). At 48 h postchallenge, the ears were collected and subjected to histological and QPCR analyses. For adoptive transfer, BLT1hi and BLT1lo DCs derived from BMDCs were sorted and loaded with 1 mM DNBS for 6 h in vitro. The hapten-loaded DCs were washed twice with PBS, followed by staining with antibodies to examine T helper cells (Th1, Th2, and Th17) and CD8+ T cells. The stained cells were analyzed with a FACSAria II flow cytometer (BD Biosciences).
Fig. 2  BLT1<sup>hi</sup> DCs migrate toward LTB<sub>4</sub> and accelerate dermatitis.  

- **A**: A chemotaxis assay was used to assess the migration of BLT1<sup>hi</sup> DCs (left) and BLT1<sup>lo</sup> DCs (right) derived from BMDCs toward LTB<sub>4</sub>. Cells were placed in the bottom chamber, and 100 nM LTB<sub>4</sub> was added to the head chamber. Representative images are shown (a, upper panels). Tracking charts for each cell type are shown (b, bottom panels). Black tracking lines indicate the cells moving forward, and red tracking lines indicate the cells moving backward (b, bottom panels). Velocity and straightness are shown in b (n > 20; error bars indicate the S.E.M.).

- **C**: The fatty acid-enriched fraction from mouse ears was analyzed for LTB<sub>4</sub> by LC-MS/MS. The time after elicitation is shown. (−): no elicitation.

- **D**: Western blot analysis for the LTA4H protein was performed with BMDC protein lysates (WT wild-type, HE heterozygous, KO homozygous knockout).

- **E**: The A23187 (calcium ionophore)-dependent production of LTB<sub>4</sub> by BMDCs was analyzed by LC-MS/MS. WT wild-type, HE hetero, KO knockout.

- **F**: H&E-stained ear sections from LTA4H WT and LTA4H KO mice are shown. Bars, 100 μm.

- **G**: Ear thickness was measured at 0, 24, and 48 h after elicitation in WT and LTA4H KO mice (n = 7).

- **H**: The schematic shows the mouse ltb4r1 gene locus targeted to generate DC-conditional BLT1 knockout mice. Genotyping was performed to evaluate the deletion of the targeted loci. The primer position is indicated in h.

- **I**: Genomic DNA

- **J**: The mRNA expression of IFN-γ in ear tissue at 48 h postelicitation was measured by QPCR. β-actin was used as an internal control. *P < 0.05; **P < 0.01; ***P < 0.001; unpaired Student’s t-test (b, j, m); two-way ANOVA with Bonferroni’s post hoc tests (c, g, l)
and 5 × 10^5 cells were injected into the footpad. Five days after DC transfer, the mice were challenged by application of 20 μl of 0.3% DNFB to the right ear.

In vitro and in vivo chemotaxis assays
To assess the migration of DCs toward LTB4 and CCL21 in vitro, both DC subsets were added to the chamber of a TaxiScan-FL optical assay device (GE Healthcare). LTB4 (100 nM) or CCL21 (250 ng/ml) was added to the head chamber to generate a concentration gradient. Phase-contrast images were captured at 10-s intervals for 10 min (Fig. 2a, b) and 1-min intervals for 30 min (Fig. 3a, b) and imported as stacks into ImageJ (NIH, Bethesda, MD, USA). Velocity and straightness (referred to as “directionality”) were calculated for more than 20 migrating cells by manual tracking using the chemotaxis and migration tools in the add-in to ImageJ software. For in vivo migration assays, BLT1hi and BLT1lo DCs were stained with CMFDA and CMTPX, respectively.38 Both DC subsets were mixed at a 1:1 ratio (1 × 10^6 cells/each) and injected into the footpad. The popliteal lymph nodes were assessed by two-photon microscopy (d) or flow cytometry (e) 24 h after DC transfer. Representative photos are shown. Bars indicate 100 μm

In vitro and in vivo chemotaxis assays
To assess the migration of DCs toward LTB4 and CCL21 in vitro, both DC subsets were added to the chamber of a TaxiScan-FL optical assay device (GE Healthcare). LTB4 (100 nM) or CCL21 (250 ng/ml) was added to the head chamber to generate a concentration gradient. Phase-contrast images were captured at 10-s intervals for 10 min (Fig. 2a, b) and 1-min intervals for 30 min (Fig. 3a, b) and imported as stacks into ImageJ (NIH, Bethesda, MD, USA). Velocity and straightness (referred to as “directionality”) were calculated for more than 20 migrating cells by manual tracking using the chemotaxis and migration tools in the add-in to ImageJ software. For in vivo migration assays, BLT1hi and BLT1lo DCs were sorted, incubated for 24 h to allow recovery, and then stained with 10 μM or 15 μM CMTPX, respectively.38 Both subsets were mixed at a 1:1 ratio (1 × 10^6 cells/each) and injected into the footpad. Twenty-four hours later, the popliteal lymph nodes were isolated, maintained in medium bubbled with 95% O2/5% CO2 at 37 °C, and examined via two-photon microscopy using a modified protocol from a previous study.39 The imaging system comprised an upright two-photon microscope (TCSPc SP5; Leica) equipped with a 20× water immersion objective (HCX APO: numerical aperture (NA), 1.0; Leica) and a femtosecond-pulsed infrared laser (Mai-Tai HP Ti:Sapphire: Spectra-Physics, Santa Clara, CA) tuned to 840 nm. Fluorescence was detected by an external nondescanned detector (NDD) with the following emission filters: 492/SP nm for the second harmonic generation (SHG), 525/50 nm for CMFDA, and 585/40 nm for CMTPX. Raw imaging data were processed using Imaris software (Bitplane, Oxford Instruments, Concord, MA).

Statistical analysis
All results are presented as the mean ± SEM. Comparisons between two groups were performed using an unpaired t-test, and comparisons among multiple groups were performed by ANOVA with post hoc tests. The threshold for statistical significance was set at p < 0.05. All statistical analyses were performed using Prism software (GraphPad Software, San Diego, CA, USA).

RESULTS
Identification of BLT1-positive and BLT1-negative DC subsets
To examine the role of BLT1 in DCs, we first analyzed the expression of BLT1 at the protein level. Due to the lack of a
monoclonal antibody specific for mouse BLT1, the expression profile of BLT1 in specific leukocyte populations has been unclear. Recently, we generated a mouse monoclonal antibody specific for mouse BLT1 (7A8) by immunizing BLT1 KO mice with cells overexpressing mouse BLT1.34 Thus, we examined BLT1 expression in BMDCs and in DCs in several mouse tissues. Surprisingly, we found that BLT1 was expressed by ~30% of CD11c + /MHC class II + spleenic DCs but not expressed by ~60% of this population (Fig. 1b). Cells showing one of these expression profiles were also observed in the BMDC and lung DC populations (Fig. 1c, f); however, no BLT1-expressing DCs were detected in the lymph nodes (Fig. 1g). We further evaluated BLT1-expressing DCs after removing F4/80-positive macrophages and Ly-6C-positive monocytes from the splenocyte population and confirmed that the removal of F4/80-positive macrophages and Ly-6C-positive monocytes did not affect the BLT1-positive and BLT1-negative DC subpopulations (Fig. S1). Immunofluorescence staining using a polyclonal antibody specific for mouse BLT1 identified two DC subsets in the mouse spleen (Fig. 1d). Next, we sorted these DC subsets from BMDCs and observed their morphologies after Diff-Quik staining. BLT1-expressing DCs (BLT1hi DCs) had a round nucleus and thin dendrites, whereas BLT1-negative and low BLT1-expressing DCs (BLT1lo DCs) had a relatively irregular nucleus, thick dendrites, and vacuoles (Fig. 1e). Collectively, these data suggest that there are two DC subsets that can be defined by the level of BLT1 expression: BLT1hi DCs and BLT1lo DCs.

Characterization of BLT1hi and BLT1lo DC subsets by various cell-surface markers

Next, we examined the expression of cell-surface markers that characterize these DC subsets. BLT1hi and BLT1lo DCs expressed MHC class II and CD80 at similar levels; however, the expression of CD86 was higher in BLT1hi DCs than in BLT1lo DCs (Fig. S2). The mouse spleen harbors three major DC subsets (CD11b+ CD8α- DCs, CD11b- CD8α+ DCs, and CD11b- CD8α+ DCs, and B220 + plasmacytoid DCs [pDCs]).

Therefore, we analyzed the relationships among these DC subsets within the BLT1hi and BLT1lo DC populations. Both the BLT1hi and BLT1lo DC subsets contained B220 + pDC and B220- conventional DC (cDC) populations (Fig. 1h, upper panels). Moreover, both DC subsets contained CD11b + DCs and CD11b- DCs in a similar ratio (Fig. 1h, bottom panels). These data suggest that BLT1hi and BLT1lo DCs exhibit similar patterns of cell-surface marker expression (and at similar levels) and that both subsets comprise known DC subpopulations including pDCs, CD11b + DCs, and CD11b- DCs (Fig. 1i).

BLT1hi DCs migrate toward LTβ2 and accelerate dermatitis

We asked whether BLT1 plays a role in DC migration because BLT1 acts as an important chemotactic receptor in neutrophils and macrophages. First, we assessed the expression and function of LTβ2. The data showed that BLT1hi DCs highly expressed BLT1 at the mRNA and protein levels (Fig. S3A, B). We also found that LTβ2 activated downstream signaling by ERK kinase only in BLT1hi DCs, not in BLT1lo DCs (Fig. S3C). We next analyzed the ability of both subsets to migrate toward LTβ2. We found that BLT1hi DCs preferentially migrated toward LTβ2 (Fig. 2a, upper and bottom; Movies S3 and S4). Although BLT1lo DCs migrated with a high velocity, the migration of BLT1hi DCs was more direct than that of BLT1lo DCs. This suggests that “random” migratory activity is high in BLT1hi DCs but that “LTβ2-dependent” migratory activity is high in BLT1lo DCs (Fig. 2b). The data also indicate that the LTβ2-BLT1 axis is required for the migration of BLT1hi DCs to inflamed tissues in which the LTβ2 concentration is highly increased (Fig. 2c). To further investigate whether the LTβ2-dependent migration of BLT1hi DCs is important in vivo, we generated LTA4H-deficient mice using a CRISPR/Cas9 system. LTA4H is a critical enzyme that converts LTA4 into LTβ2 (Fig. 1a). The Aat II restriction enzyme site within exon 3 of the mouse LTA4H gene was mutated to introduce a frameshift mutation. This resulted in a band representing the cleaved LTA4H gene in WT bone marrow-derived DCs (BMDCs) and the uncleaved LTA4H gene in LTA4H KO BMDCs (Fig. S4). LTA4H deficiency was confirmed by Western blot analysis of BMDC lysates (Fig. 2d). We confirmed that LTβ2 production was abrogated in LTA4H KO BMDCs (Fig. 2e). Next, we examined the effects of LTA4H deficiency on a mouse model of allergic contact dermatitis. Ear swelling in LTA4H KO mice was ameliorated significantly (Fig. 2f, g). The infiltration of LTA4H KO mouse ear tissue by inflammatory cells was less severe than that in the ear tissue of WT mice (Fig. 2f). These results confirm that the LTβ2-BLT1 axis is crucial for the aggravation of allergic dermatitis in vivo. To investigate the cell-specific role of the LTβ2-BLT1 axis in DCs, we further generated DC-specific BLT1 cKO mice by crossing BLT1flox/fox with CD11c-Cre transgenic (Tg) mice (Fig. 2h). As expected, splenic DCs and BMDCs from BLT1flox/foxCD11c-Cre (BLT1 cKO) mice harbored a genomic deletion in BLT1 (Figs. 2i and S5A, C). These cells also showed reduced mRNA expression of BLT1 (Figs. 2j and S5B). Next, we analyzed the effects of BLT1-deficient DCs on allergic dermatitis. As shown in Fig. 2k, l, ear swelling induced by DNFB was less severe in BLT1 cKO mice than in WT mice. In addition, the expression of IFN-γ in the ears of BLT1 cKO mice was suppressed (Fig. 2m). Taken together, these data suggest that the LTβ2-BLT1 axis in DCs plays an important role in migration toward LTβ2-enriched inflammatory areas and amplifies hapten-induced allergic contact dermatitis.

BLT1lo DCs migrate toward CCL21 and lymph nodes more than do BLT1hi DCs

Because DC migration to the lymph nodes is crucial for allergic dermatitis, we investigated the migratory activity of both DC subsets in response to CCL21, a “homing” chemokine expressed in the lymph nodes. Surprisingly, BLT1lo DCs showed greater migration toward CCL21 than did BLT1hi DCs (Fig. 3a, upper and bottom; Movies S3 and S4). BLT1lo DCs migrated more quickly and more directly than BLT1hi DCs (Fig. 3b). We further asked whether BLT1lo DCs migrate preferentially toward the lymph nodes in vivo. Sorted BLT1hi DCs and BLT1lo DCs were stained with 5-chloromethylfluorescein diacetate (CMFDA) and CMTFX, respectively, and then mixed at a 1:1 ratio. They were then injected into the footpad of naïve mice. Twenty-four hours later, more migrated BLT1lo DCs were observed by 2-photon microscopy in the popliteal lymph nodes (Figs. 3c, d and S6; Movie S5). This preferential migratory activity of BLT1lo DCs was also confirmed by flow cytometric analysis (Fig. 3e). These data suggest that BLT1lo DCs preferentially migrate toward CCL21, which is enriched in the lymph nodes.

Comparative analysis of the transcriptomic profiles of BLT1hi and BLT1lo DCs

Next, we compared the transcriptomic profiles of BLT1hi and BLT1lo DCs with 207 profiles derived from granulocytes, B cells, NK cells, T cells, NK T cells, macrophages, monocytes, and DCs.40 The BLT1hi and BLT1lo DC subtypes localized next to each other within the DC cluster (Fig. S7). Next, we exposed both subsets to various PAMPs, including lipopolysaccharide (LPS) and CpG DNA, for 4 h and then performed microarray analysis. We extracted 601 probes (574 genes) highly expressed by BLT1hi DCs and 445 probes (404 genes) highly expressed by BLT1lo DCs under each condition from gene sets with high and common expression in both DC populations (Fig. 4a, Tables S1 and S2). The extracted genes were subjected to Gene Ontology (GO) analysis; the top 5 GO terms for the genes highly expressed by BLT1hi DCs (n = 231) are shown in Fig. 4b, and those for the genes highly expressed by BLT1lo DCs (n = 95) are shown in Fig. 4c. These genes (total 326 genes) were arranged in protein categories (Fig. 4d, Tables S3 and S4). Taken together, the data from the comparative transcriptomic analysis suggest that BLT1hi and BLT1lo DCs are very similar but may differ
in terms of their inflammatory defense responses, immune responses, and ability to activate T cells.

BLT1hi DCs preferentially induce Th1 differentiation by producing IL-12

Unbiased microarray analysis demonstrated that BLT1hi DCs expressed high levels of IL-12 (Fig. 4d). IL-12, which induces Th1 differentiation, comprises IL-12p35 and IL-12p40. First, we checked the expression of IL-12p35 and IL-12p40 by BLT1hi and BLT1lo DCs. Consistent with the microarray data, BLT1 hi DCs expressed high levels of IL-12p35; however, the subsets expressed IL-12p40 at the same level (Fig. 5a, b). Furthermore, only BLT1hi DCs generated a heterodimeric IL-12p70 protein (Fig. 5c). Next, we used a coculture system to examine Th1 induction by both DC subsets. CD4+ T cells from OT-II Tg mice were cocultured with each DC subset in the presence of an ovalbumin (OVA) peptide. We found that CD4+ T cells preferentially differentiated into interferon (IFN)-γ positive Th1 cells when cocultured with BLT1hi DCs (Fig. 5d). The addition of CpG DNA to the coculture system enhanced IFN-γ production, especially in BLT1hi DC cultures. This BLT1hi DC-dependent IFN-γ production was blocked with neutralizing antibodies specific for IL-12p35 or IL-12p40 (Fig. 5e). Next, we used a delayed-type contact dermatitis model generated by the transfer of antigen-loaded DCs into naïve mice to analyze the in vivo functions of both DC subsets. Sorted BLT1lo or BLT1hi DCs were loaded with sodium 2,4-dinitrobenzenesulfonate (DNBS) for 6 h and then injected into the footpad of naïve mice. Five days later, the mouse ears were treated with 2,4-dinitrofluorobenzene (DNFB) (Fig. 5f). At 48 h posttreatment, the ears of the mice receiving BLT1lo DCs were thicker than those of the mice receiving BLT1hi DCs (Fig. 5g, h). Moreover, IFN-γ was expressed at higher levels in the ears of the BLT1hi DC-transferred mice than in those of the BLT1lo DC-transferred mice (Fig. 5i). Taken together, these data suggest that BLT1hi DCs induce Th1-dependent allergic contact dermatitis via specific production of IL-12 both in vitro and in vivo.

BLT1lo DCs preferentially induce T cell proliferation by producing IL-2

Next, we examined the specific function of BLT1lo DCs. First, we reanalyzed the microarray data and found that BLT1lo DCs expressed high levels of IL-2 (Fig. 4d). Because DC-derived IL-2 is crucial for the initiation of T cell proliferation,42 we next examined the expression of IL-2 by both DC subsets. As expected, we found that BLT1lo DCs expressed high mRNA and protein levels of IL-2 (Fig. 6a, b). IL-2 supported the proliferation of splenic CD4+ T cells derived from OT-II Tg mice (Fig. 6c). Next, we used a coculture system to examine T cell proliferation induced by both DCs. When CD4+ T cells from OT-II Tg mice were cocultured with BLT1lo DCs in the presence of an OVA peptide, they proliferated much faster.
Fig. 5  BLT$_{1}^{hi}$ DCs preferentially induce Th1 differentiation by producing IL-12p35. BLT$_{1}^{hi}$ DCs preferentially induce Th1 differentiation by producing IL-12p35. QPCR analysis of IL-12p35 (a) and IL-12p40 (b) expression was performed. Both DC subsets were treated with CpG DNA (500 nM) for 4 h. GAPDH was used as an internal control. c Both DC subsets were treated with CpG DNA for 24 h, and the supernatants were collected. The IL-12p70 protein in the supernatant was quantified by CBA analysis (n = 3; error bars indicate the S.E.M.). d, e Sorted BLT$_{1}^{hi}$ (upper panels) and BLT$_{1}^{lo}$ BMDCs (bottom panels) were cocultured for 3 days with splenic CD4$^+$ T cells derived from OT-II Tg mice (ratio 1:4) in the presence (CpG) or absence (CON) of CpG DNA (500 nM). The cells were stained for intracellular IFN-γ and analyzed by flow cytometry. Cells were incubated for 3 days with neutralizing antibodies specific for IL-12p35 (1 μg/ml) or IL-12p40 (1 μg/ml) to examine the effects of IL-12 on Th1 differentiation. f The schematic shows the experimental flow for DC transfer into the footpad. g, h, i Both DC subsets were loaded with DNBS in vitro for 6 h and then injected into the footpad. Five days later, mouse ear tissue was treated with DNFB, and ear thickness was measured (g). Forty-eight hours after elicitation, ear tissue was collected and stained with H&E (h). Bars, 100 μm. i The mRNA expression of IFN-γ in induced mouse ear tissue was measured by QPCR. β-actin was used as an internal control (n = 3; error bars indicate the S.E.M.). *P < 0.05; **P < 0.01; ***P < 0.001; unpaired Student’s t-test (i); one-way ANOVA with Bonferroni’s post hoc tests (a, b, c, e); two-way ANOVA with Bonferroni’s post hoc test (h)
Fig. 6  BLT1<sup>lo</sup> DCs preferentially induce T cell proliferation by producing IL-2.  

**A.** IL-2 mRNA expression in BLT1<sup>hi</sup> and BLT1<sup>lo</sup> DCs treated with CpG DNA (500 nM) for 4 h and 24 h, followed by qPCR. 
**B.** IL-2 protein production by BLT1<sup>hi</sup> and BLT1<sup>lo</sup> DCs in response to CpG DNA. 
**C.** T cell proliferation assay with BLT1<sup>hi</sup> and BLT1<sup>lo</sup> DCs treated with CpG DNA (500 nM) for 4 h and 24 h. 

**D.** T cell proliferation assay with BLT1<sup>hi</sup> and BLT1<sup>lo</sup> DCs treated with recombinant IL-2 protein (10 ng/ml) or vehicle (CON). 

**E.** Flow cytometric analysis of proliferating CD4<sup>+</sup> T cells in the presence of a neutralizing antibody against murine IL-2. A rat IgG2a kappa isotype control antibody was added to the control group. 

**F.** Flow cytometric analysis of proliferating CD4<sup>+</sup> T cells in the presence of an OVA peptide. 

**G.** Flow cytometric analysis of proliferating CD4<sup>+</sup> T cells in the presence of an OVA peptide and a neutralizing antibody against murine IL-2. 

**H.** Flow cytometric analysis of proliferating CD4<sup>+</sup> T cells in the presence of an OVA peptide and a neutralizing antibody against murine IL-2. 

**I.** The schematic model shows how the novel BLT1<sup>hi</sup> and BLT1<sup>lo</sup> DC subsets control skin inflammation. There are two DC subsets, BLT1<sup>hi</sup> and BLT1<sup>lo</sup> DCs, in peripheral tissues. BLT1<sup>lo</sup> DCs migrate preferentially toward draining lymph nodes and produce high amounts of IL-2 to induce T cell proliferation. On the other hand, BLT1<sup>hi</sup> DCs migrate toward LTB<sub>4</sub>, which is produced by inflammatory cells, such as neutrophils, in inflammatory areas. BLT1<sup>hi</sup> DCs produce large amounts of IL-12, which boosts Th1 differentiation. Expanded differentiated Th1 cells produce IFN-γ, which drives spongiosis and edema in inflamed peripheral tissues.
than when cocultured with BLT1hi DCs plus the peptide (Fig. 6d, e). This BLT1hi DC-dependent CD4+ T cell proliferation was significantly blocked with a neutralizing antibody specific for IL-2 (Fig. 6f). Therefore, we asked whether BLT1lo DCs have a much greater potential to induce antigen-dependent T cell proliferation in vivo. OVA peptide-loaded DCs were injected intravenously into OT-II Tg mice. The spleen was then removed to examine antigen-dependent T cell proliferation. We observed splenomegaly and increased splenocyte numbers only in the mice receiving BLT1lo DCs (Fig. 6g, h). Collectively, these data suggest that BLT1lo DCs have a greater potential to induce T cell proliferation than do BLT1hi DCs, likely via specific production of IL-2. Collectively, our data demonstrate that BLT1lo DCs produce IL-2 to drive T cell proliferation after migrating to CCL21-rich lymph nodes, whereas BLT1hi DCs migrate toward peripheral LTB4-rich inflammatory areas to produce IL-12 to drive peripheral Th1 differentiation to deliver a “final boost” to tightly control Th1-dependent immune responses (Fig. 6i).

**DISCUSSION**

BLT1, which is expressed by neutrophils, eosinophils, macrophages, DCs, CD4+ T cells, and CD8+ T cells, plays roles in innate and acquired immune responses and several immunological disorders. Previously, we and others have reported that systemic BLT1 deficiency ameliorates Th1-dependent contact dermatitis, Th2-dependent asthma, Th17-dependent EAE, and rheumatoid arthritis.26,28,31,32,43 Despite its importance in immunity, the cell-specific role of BLT1 is largely unknown due to the lack of cell-specific BLT1 cKO mice and specific monoclonal antibodies. Here, we generated DC-specific BLT1 cKO mice. A BLT1 cKO mouse model of allergic contact dermatitis showed decreased ear swelling and IFN-γ expression, clearly suggesting that BLT1 expression by DCs plays a crucial role in Th1-dependent skin inflammation (Fig. 6i). A growing body of evidence shows that lipid mediators, including LTB4, PGs, resolvins, and sphingolipids (and their cognate receptors), act as crucial immunomodulators. Among these factors, the 51P receptor (51P1) is a target for the treatment of multiple sclerosis.7,8 In addition, antagonists of the mRNA level. Here, we found that both BLT1hi and BLT1lo DCs showed a similar phenotype with respect to the expression of cell-surface proteins such as MHC class II, CD80, CD86, B220, and CD11b (BLT1 is the exception). However, comparative transcriptomic profiling revealed that BLT1hi DCs expressed high levels of IL-12, whereas BLT1lo DCs expressed high levels of IL-2, resulting in distinct functions (i.e., preferential effects on Th1 differentiation and T cell proliferation, respectively, in vitro and in vivo). At present, we do not know how these distinct cytokine profiles are generated. We also concluded that LTB4-BLT1 signaling is unlikely to be the reason for the difference (Fig. S8). Thus, other as-yet-unidentified mechanisms may exist. One possibility is that intracellular signaling cascades differ between BLT1hi and BLT1lo DCs. Our in silico analysis using the Chromatin Immunoprecipitation (ChIP)-Atlas (http://chip-atlas.org) revealed that the transcription factors regulating IL-12p35 and IL-2 are different (i.e., interferon regulatory factor 1 [IRF1], which regulates IL-12p35, and CEBP-β, which regulates IL-2, are localized within acetylated H3 and H3K4me1-enriched enhancer regions on each gene locus) (Fig. S9). In addition, although we used the same TL9 ligand (CpG DNA), we found that the activation of intracellular signaling pathways in BLT1hi and BLT1lo DCs was different. These data lead us to hypothesize that the signaling downstream of TL9 differs between BLT1hi and BLT1lo DCs, resulting in the activation of different transcription factors and induction of different proteins. Another possibility is that the epigenetic status of each DC subset differs. The microarray data showed differential expression of several epigenetics-modifying enzymes in BLT1hi and BLT1lo DCs. In particular, BLT1hi DCs express high levels of a histone demethylase (Jumonji Domain-containing Histone Demethylase [Jhdm] 1D) and DNA demethylase (Ten-Eleven Translocation [TET] 1), whereas BLT1lo DCs express high levels of a different histone demethylase, Jhdm1b (Tables S1 and S2). Importantly, BLT1, IL-12p35, IL-12p40, and IL-2 are regulated either directly or indirectly by epigenetic mechanisms.49-55 In a future study, we will focus on the molecular mechanisms underlying the differential regulation of cytokine expression in BLT1hi and BLT1lo DCs at the intracellular signaling and/or epigenetic levels.

Another interesting finding was that BLT1hi DCs preferentially migrated toward LTB4, which is produced in inflamed peripheral areas (Fig. 2) rather than the lymph nodes. In contrast, BLT1lo DCs exhibited preferential migration toward CCL21, which is produced in the lymph nodes (Fig. 3). These data suggest that BLT1hi and BLT1lo DCs have different migratory patterns. The fundamental function of DCs is to capture antigens and migrate to draining lymph nodes. However, recent reports have shown that DC migration toward peripheral areas is crucial for fine-tuning immune responses.46,56 Migrated DCs form clusters and drive peripheral T cell expansion and B cell-mediated immunity; thus, DC migration to the lymph nodes and inflamed peripheral areas is important for regulating acquired immunity. These reports lead us to hypothesize that the formerly identified canonical DCs are in fact BLT1hi DCs and the latter noncanonical DCs are in fact BLT1lo DCs. In the future, we will investigate the possibility that BLT1hi DCs contribute to the formation of inducible peripheral lymphoid clusters, including inducible skin-associated lymphoid tissue (isALT) and inducible bronchus-associated lymphoid tissue (iBALT). One area that remains to be explored is the mechanism underlying the differences in the motility of these DCs. Although the expression of the mRNA transcript encoding C-C chemokine receptor type 7 (CCR7), a receptor for CCL21, was comparable between BLT1hi and BLT1lo DCs, the population of CCR7-positive cells was higher in bone marrow-derived and splenic BLT1lo DCs (Fig. S10). This difference could, at least in part, explain the distinct migratory activities of both DC subsets. In addition, we speculated that mechanisms other than the CCL21/CCR7 axis may be involved. One possible hypothesis is that the PGE2-EF4 axis is highly active in BLT1lo DCs, resulting in preferential migration of BLT1lo DCs toward the lymph nodes. The PGE2-EP2/4 axis was shown to accelerate DC migration toward the lymph nodes in both mice and humans through intracellular signaling cross-talk and matrix metalloproteinase upregulation without alterations in the cell-surface expression of CCR7.57-60 The importance of the PGE2-EF4 axis in DC migration is also highlighted in the report by Kabashima et al., which showed impaired migration of Langhansker cells and reduced skin immune responses in EP4 KO mice.61 Our microarray data showed that BLT1lo DCs expressed higher levels of...
EP4 (Ptger4) mRNA than BLT1hi DCs; moreover, BLT1lo DCs produced more PGE2 than BLT1hi DCs (data not shown). CCL21 drives CCR7-dependent increases in the levels of intracellular Caa2+, which generates PGE2 and results in increased cell migration via signaling by the EP4 receptor, which is expressed at high levels on BLT1lo DCs. The contribution of the PGE2-EP4 axis to the preferential migration of BLT1lo DCs toward CCL21 and/or the lymph nodes will be investigated in a future study.

In summary, we generated LTAA-H-deficient mice and BLT1 cKO mice and used them to show that BLT1 intensifies DC-mediated immune responses. We also identified novel DC subsets, which were defined by differential expression of BLT1 (high and low). These subsets show distinct cytokine-producing and migratory profiles. The data provide new insight into our understanding of the role of BLT1 in immune responses and suggest a potential therapeutic target in immunological disorders, including allergic contact dermatitis.

ACKNOWLEDGEMENTS
This work was supported by Grants-in-Aid for Scientific Research (KAKENHI) from the Ministry of Education, Culture, Sports, Science, and Technology (MEXT) of the Japan Society for the Promotion of Science (grant numbers JP22116001, JP22116002, JP15H05901, JP15H05904, JP15H04708, and JP18H02627 to T.Y.; JP25660233, JP15K19032 and JP17K08664 to T.K.; JP15K08316 and JP18K09623 to K.S.; and JP15K00320 and JP16K08596 to T.O.). By the AMED-CREST (JP20gm1210006 to K.S.) and by grants from the Naito Foundation, the Ono Medical Research Foundation, the Uehara Memorial Foundation, the Mitsubishi Foundation, and the Takeda Science Foundation. The study was also supported (in part) by a Grant-in-Aid (S1311011 to T.Y.) from the Foundation for Strategic Research Projects in Private Universities of the MEXT and by a grant from the Institute for Environmental and Gender-Specific Medicine. We thank the Research Center for Human Disease Modeling (KyuShu University) and the Research Support Center of the Division of Molecular and Biochemical Research (Juntendo University) for providing technical support. We also thank Mr. Haruyasu Kato for generating the rabbit anti-mouse BLT1 polyclonal antibody and members of our laboratory for advice and helpful discussion.

AUTHOR CONTRIBUTIONS
T.K., K.S., and T.Y. designed all experiments. T.K., K.S., S.T., M.O., H.U., K.K., C.M., E.N., N.T., and J.K. performed the experiments. T.K., F.S., K.S., T.O., T.J., S.I., Y.F., M.I., Y.S., and T.Y. analyzed the data. T.K., K.S., and T.Y. wrote the manuscript.

ADDITIONAL INFORMATION
The online version of this article (https://doi.org/10.1038/s41423-020-00559-7) contains supplementary material.

Competing interests: The authors declare no competing interests.

REFERENCES
1. GeurtsvanKessel, C. H. et al. Dendritic cells are crucial for maintenance of tertiary lymphoid structures in the lung of influenza virus-infected mice. J. Exp. Med. 206, 2339–2349 (2009).
2. Natsuki, Y. et al. Perivascular leukocyte clusters are essential for efficient activation of effector T cells in the skin. Nat. Immunol. 15, 1064–1069 (2014).
3. Natsuki, Y. & Kabashima, K. Inducible lymphoid clusters, iSLATs, in contact dermatitis: a new concept of acquired cutaneous immune responses. Med. Mol. Morphol. 49, 127–132 (2016).
4. Kuroda, E. et al. Inhaled leucotriene B4 and BLT1 control cytotoxic effector T cell recruitment to inflammatory lesions. J. Exp. Med. 206, 633–640 (2009).
5. Yao, C. et al. Prostaglandin E2 promotes immune infiltration through Th1 cell differentiation and Th17 cell expansion. Nat. Med. 15, 633–640 (2009).
6. Boniface, K. et al. Prostaglandin E2 regulates Th17 cell differentiation and function through cyclic AMP and EP2/EP4 receptor signaling. J. Exp. Med. 206, 535–548 (2009).
7. Brinkmann, V. et al. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat. Rev. Drug Discov. 9, 883–897 (2010).
8. Kappos, L. et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N. Engl. J. Med. 362, 387–401 (2010).
9. Li, H. & Zhang, X. Oral cladribine and fingolimod for relapsing multiple sclerosis. N. Engl. J. Med. 362, 1737–1739 (2010). author reply 1739-40.
10. Mann, H. Oral cladribine and fingolimod for relapsing multiple sclerosis. N. Engl. J. Med. 362, 1738 (2010). author reply 1739-40.
11. Carroll, W. M. Oral therapy for multiple sclerosis–sea change or incremental step? N. Engl. J. Med. 362, 456–458 (2010).
12. Cohen, J. A. et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N. Engl. J. Med. 362, 402–415 (2010).
13. Sawada, Y. et al. Resolvin E1 inhibits dendritic cell migration in the skin and attenuates contact hypersensitivity responses. J. Exp. Med. 212, 1921–1930 (2015).
14. Kikuki, Y. et al. Lymphoid tissue phospholipase A2 group IIID resolves contact hypersensitivity by driving anti-inflammatory lipid mediators. J. Exp. Med. 210, 1217–1234 (2013).
39. Suzuki, K., Giorgorova, I., Phan, T. G., Kelly, L. M. & Cyster, J. G. Visualizing B cell capture of cognate antigen from follicular dendritic cells. J. Exp. Med. 206, 1485–1493 (2009).
40. Cohn, L. & Delamarre, L. Dendritic cell-targeted vaccines. Front. Immunol. 5, 255 (2014).
41. Miller, J. C. et al. Deciphering the transcriptional network of the dendritic cell lineage. Nat. Immunol. 13, 888–899 (2012).
42. Granucci, F. et al. Inducible IL-2 production by dendritic cells revealed by global gene expression analysis. Nat. Immunol. 2, 882–888 (2001).
43. Zhou, J. et al. BLT1 in dendritic cells promotes Th1/Th17 differentiation and its deficiency ameliorates TNBS-induced colitis. Cell Mol. Immunol. 15, 1047–1056 (2018).
44. Matsunaga, Y. et al. Leukotriene B4 receptor BLT2 negatively regulates allergic airway eosinophilia. FASEB J. 27, 3306–3314 (2013).
45. Gelfand, E. W. Importance of the leukotriene B4-BLT1 and LTB4-BLT2 pathways in asthma. Semin Immunol. 33, 44–51 (2017).
46. Peters-Golden, M. Expanding roles for leukotrienes in airway inflammation. Curr. Allergy Asthma. Rep. 8, 367–373 (2008).
47. Niimi, A. Cough, asthma, and cysteinyi-leukotrienes. Pulm. Pharm. Ther. 26, 514–519 (2013).
48. Hori, T. et al. Na(+)–mimicking ligands stabilize the inactive state of leukotriene B4 receptor BLT1. Nat. Chem. Biol. 14, 262–269 (2018).
49. Kato, K., Yokomizo, T., Izumi, T. & Shimizu, T. Cell-specific transcriptional regulation of human leukotriene B(4) receptor gene. J. Exp. Med. 192, 413–420 (2000).
50. Chen, C. J., Hou, J. W. & Chiang, B. L. The difference in immune response and IL-12p35 methylation between newborns and adults. J. Biomed. Sci. 21, 76 (2014).
51. Schaller, M. et al. Epigenetic regulation of IL-12-dependent T cell proliferation. J. Leukoc. Biol. 98, 601–613 (2015).
52. Xu, J. et al. Nuclear carbonic anhydrase 6B associates with PRMT5 to epigenetically promote IL-12 expression in innate response. Proc. Natl Acad. Sci. USA 114, 8620–8625 (2017).
53. Li, M. F. et al. High glucose increases the expression of inflammatory cytokine genes in macrophages through H3K9 methyltransferase mechanism. J. Interferon Cytokine Res 36, 48–61 (2016).
54. Bandyopadhyay, S., Montagna, C. & Macian, F. Silencing of the Il2 gene transcription is regulated by epigenetic changes in anergic T cells. Eur. J. Immunol. 42, 2471–2483 (2012).
55. Wang, J., Barke, R. A. & Roy, S. Transcriptional and epigenetic regulation of interleukin-2 gene in activated T cells by morphine. J. Biol. Chem. 282, 7164–7171 (2007).
56. Nagatake, T. et al. Immunological association of inducible bronchus-associated lymphoid tissue organogenesis in Ag85B-rHPIV2 vaccine-induced anti-tuberculosis mucosal immune responses in mice. Int. Immunol. 30, 471–481 (2018).
57. Scandella, E., Men, Y., Gillessen, S., Forster, R. & Groettrup, M. Prostaglandin E2 is a key factor for CCR7 surface expression and migration of monococyte-derived dendritic cells. Blood 100, 1354–1361 (2002).
58. Scandella, E. et al. CCL19/CCL21-triggered signal transduction and migration of dendritic cells requires prostaglandin E2. Blood 103, 1595–1601 (2004).
59. Legler, D. F., Krause, P., Scandella, E., Singer, E. & Groettrup, M. Prostaglandin E2 is generally required for human dendritic cell migration and exerts its effect via EP2 and EP4 receptors. J. Immunol. 176, 966–973 (2006).
60. Yan, J. H., Khayrullina, T. & Ganea, D. PGE2-induced metalloproteinase-9 is essential for dendritic cell migration. Blood 111, 260–270 (2008).
61. Kabashima, K. et al. Prostaglandin E2-EP4 signaling initiates skin immune responses by promoting migration and maturation of Langerhans cells. Nat. Med. 9, 744–749 (2003).